423 related articles for article (PubMed ID: 32744334)
1. Breakthrough invasive fungal infections: Who is at risk?
Jenks JD; Cornely OA; Chen SC; Thompson GR; Hoenigl M
Mycoses; 2020 Oct; 63(10):1021-1032. PubMed ID: 32744334
[TBL] [Abstract][Full Text] [Related]
2. [Current indications for voriconazole in onco-hematological patients].
Jarque I; Sanz MA
Rev Iberoam Micol; 2007 Sep; 24(3):213-6. PubMed ID: 17874858
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.
Winston DJ; Limaye AP; Pelletier S; Safdar N; Morris MI; Meneses K; Busuttil RW; Singh N
Am J Transplant; 2014 Dec; 14(12):2758-64. PubMed ID: 25376267
[TBL] [Abstract][Full Text] [Related]
4. Changing patterns and trends in systemic fungal infections.
Richardson MD
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i5-i11. PubMed ID: 16120635
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
[TBL] [Abstract][Full Text] [Related]
6. Distribution of invasive fungal infections: Molecular epidemiology, etiology, clinical conditions, diagnosis and risk factors: A 3-year experience with 490 patients under intensive care.
Borjian Boroujeni Z; Shamsaei S; Yarahmadi M; Getso MI; Salimi Khorashad A; Haghighi L; Raissi V; Zareei M; Saleh Mohammadzade A; Moqarabzadeh V; Soleimani A; Raeisi F; Mohseni M; Mohseni MS; Raiesi O
Microb Pathog; 2021 Mar; 152():104616. PubMed ID: 33212195
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
8. Emerging systemic fungal infections.
Galimberti R; Torre AC; Baztán MC; Rodriguez-Chiappetta F
Clin Dermatol; 2012; 30(6):633-50. PubMed ID: 23068151
[TBL] [Abstract][Full Text] [Related]
9. Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.
Anesi JA; Baddley JW
Infect Dis Clin North Am; 2016 Mar; 30(1):277-96. PubMed ID: 26739603
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
11. Fungal infections in cancer patients: an escalating problem.
Samonis G; Bafaloukos D
In Vivo; 1992; 6(2):183-93. PubMed ID: 1525339
[TBL] [Abstract][Full Text] [Related]
12. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
Playford EG; Webster AC; Sorell TC; Craig JC
Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
[TBL] [Abstract][Full Text] [Related]
13. [Invasive fungal infections in patients with hematological malignancies: a clinical approach].
García-Ruiz JC; Pontón J
Med Clin (Barc); 2000 Sep; 115(8):305-12. PubMed ID: 11093887
[No Abstract] [Full Text] [Related]
14. [Mycoses and their treatment in malignant hemopathies].
Martino P; Girmenia C
Recenti Prog Med; 1999 Mar; 90(3):160-8. PubMed ID: 10228357
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007).
Raghuram A; Restrepo A; Safadjou S; Cooley J; Orloff M; Hardy D; Butler S; Koval CE
Liver Transpl; 2012 Sep; 18(9):1100-9. PubMed ID: 22577087
[TBL] [Abstract][Full Text] [Related]
16. Fungal infections in nontransplant patients with hematologic malignancies.
Segal BH; Bow EJ; Menichetti F
Infect Dis Clin North Am; 2002 Dec; 16(4):935-64, vii. PubMed ID: 12512188
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.
Douglas AP; Slavin MA
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1165-1177. PubMed ID: 27710140
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
[TBL] [Abstract][Full Text] [Related]
19. Recent advances and challenges in the treatment of invasive fungal infections.
Shao PL; Huang LM; Hsueh PR
Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
[TBL] [Abstract][Full Text] [Related]
20. Antifungal prophylaxis in lung transplantation.
Neoh CF; Snell G; Levvey B; Morrissey CO; Stewart K; Kong DC
Int J Antimicrob Agents; 2014 Sep; 44(3):194-202. PubMed ID: 25123811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
